Toll-like receptor 4 gene in IBD: further evidence for genetic heterogeneity in Europe

There is now strong evidence implicating the enteric flora in the aetiology of inflammatory bowel disease (IBD), and identification of CARD15 (NOD2) as a pattern recognition receptor (PRR) has given novel insights into host-bacteria interactions. CARD15 is implicated as the intracellular sensor of muramyl dipeptide, a highly conserved bacterial peptidoglycan motif, and raises the question of whether other PRRs are involved in the pathogenesis of Crohn’s disease (CD).

Toll-like receptor 4 (TLR4), in combination with CD14, LBP, and MD-2, acts as the PRR for the lipid A moiety of lipopolysaccharide, a major component of gram negative bacteria. Two common cosegregating polymorphisms of this gene have been described in humans, Asp299Gly and Thr399Ile. Asp299Gly has been associated with reduced bronchial responsiveness following lipopolysaccharide stimulation although recent data have questioned the functional effect of this variant.

We therefore note with interest the article in Crohn’s disease relatives (CD).

Asp299Gly, and no association with CD. In contrast with the Belgian data, this group identified an association of Thr399Ile with UC in 480 Scottish patients with IBD and found no association with either CD or UC.

Why are these data sets discrepant? Issues relating to statistical power, population stratification in case control studies, and phenotypic heterogeneity within IBD may contribute but we suggest more detailed examination of these data (table 1) provides evidence for genetic heterogeneity between populations in Europe.

CD genotype frequencies were very similar in the Leuven and Edinburgh data sets, and not significantly different from the German CD results. However, allele frequencies in healthy controls were significantly different in the Scottish population compared with European controls (8.8% v 4.6%; p = 0.008, odds ratio 1.47 (confidence interval 1.2–3.5)).

It is clearly relevant that a strong suggestion of heterogeneity between populations was given in the original description of Arbour and Lorenz where control population allele frequencies for Asp299Gly ranged from 3.3% to 7.9% in French and North American data sets. It is noteworthy that these allele variants were absent in the Japanese population.

Moreover, there is now compelling evidence for genetic heterogeneity between populations for CARD15 in both healthy controls and CD patients. Variant alleles are absent from Asian CD and control populations and exist at a lower frequency in African American CD patients and Ghanaian controls (carriage 1%).

There is also striking evidence for heterogeneity within Europe, and evidence for a geographical North-South gradient in gene effect, as for the CFTR delta 508 mutation in cystic fibrosis. Lower CARD15 (NOD2) frequencies in CD have been reported from Scotland and Finland and are absent in a small Icelandic population.

These data illustrate further the real difficulties in candidate gene analysis in complex diseases. It is likely that the contribution of individual genetic determinants will differ between populations. We suggest that further genetic (as well as functional) data are required before the exact contribution of inherited variants of the TLR4 gene can be confirmed.

Table 1

<table>
<thead>
<tr>
<th>Patient numbers (allele frequencies)</th>
<th>CD genotype frequencies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Wild-type</td>
</tr>
<tr>
<td>Leuven 334 (11.0%)</td>
<td>163 (10.0%)</td>
</tr>
<tr>
<td>Munich 102 (7.0%)</td>
<td>98 (9.0%)</td>
</tr>
<tr>
<td>Edinburgh 234 (10.3%)</td>
<td>246 (6.8%)</td>
</tr>
</tbody>
</table>

HC allele frequencies differed between Edinburgh and Leuven (p<0.02, odds ratio 1.35 (confidence interval 1.1–4.5)) and those between Edinburgh and Leuven approached significance (p = 0.05).

References


Author’s reply

We would like to thank Arnott et al for their interesting comments. Needless to say, we all agree that great caution should apply when presenting positive or negative association studies because of issues such as sample size, cryptic population substructure, and phenotype misclassification. To this end, a transmission disequilibrium test (TDT) should always be performed to alleviate skepticism and doubts. It is true that a clear genetic heterogeneity emerges when examining NOD2 and toll-like receptor 4 (TLR4) carriage frequencies in patients with Crohn’s disease in Europe, North America, and Asia. That Crohn’s disease is a heterogeneous and polygenic disease is obvious in the light of recent genome wide screens. However, if multiple genes contribute to Crohn’s disease, their relative impact may vary from one phenotype to another (or from one Crohn’s...
Oesophageal entrapment of wireless capsule endoscopy in valvular patients

Wireless capsule endoscopy is an emerging new method of examining the small bowel. Its indications are currently widening, and occult and gastrointestinal bleeding of obscure origin, chronic diarrhoea and malabsorption syndromes, and suspicion of a small bowel neoplasm are now accepted indications. Complications are rare, the main one being that it can become a cause of foreign body, with strictures or diverticula inaccessible to flexible endoscopic retrieval. The incidence in published series range from 1% to 5%, and all were managed with a surgical or endoscopic procedure.

We present a complication seen in two of our patients, with no consequences to their health or management, but with an impact on examination accuracy and usefulness: oesophageal entrapment in an extra oesophageal vascular compression.

Patient 1 was a 74-year-old man with a history of a prosthetic metallic mitral valve and congestive heart failure who had suffered three episodes of obscure overt gastrointestinal bleeding. In his community hospital, he had undergone upper and lower endoscopy twice, radioisotope bleeding scans, magnetic resonance imaging angiography, and conventional angiography but the source of the gastrointestinal bleeding was not found. He needed oral iron supplementation but this did not correct his iron deficiency anaemia. Previous radiographic contrast studies of the small bowel had been normal. It was then referred to our unit for a capsule endoscopy examination. After the patient swallowed the capsule, we could see that without an apparent intrinsic stricture, the capsule was retained in the second third of the oesophagus for approximately four hours, progressing to the stomach after this time with no apparent manoeuvre or fluid ingestion (fig 1). The study could not be completed to the terminal ileum because batteries became exhausted at the level of the proximal ileum. Nevertheless, we could see three bleeding jejunal ulcers as the cause of his gastrointestinal bleeding.

Our second patient was a 72-year-old woman with a mitral prosthetic valve and chronic auricular fibrillation. She had undergone upper and lower gastrointestinal endoscopy and mesenteric angiography because she had passed dark stools with severe anaemia, on repeated occasions. A plain chest x ray showed marked cardiomegaly. She was referred to our centre for a small bowel capsule endoscopy examination. The capsule got stuck at a pulsatile area in the distal oesophagus, staying there for up to three hours and passing afterwards without a specifically related cause (fig 2). The study
was also suboptimal because the patient had ingested some fluids and food that interfered with small bowel vision.

This complication of wireless capsule endoscopy has not previously been reported. An elongated aorta was probably the cause of extrinsic pulsate compression of the thoracic oesophagus in our first case, and a dilated auricular cavity in the second. In both patients upper endoscopy had been performed twice and no strictures were identified.

Although not a life threatening complication, it limited the procedure results in both cases, leading to suboptimal results. A plain chest x-ray or accurate oesophageal radiographic contrast studies, previous to the wireless capsule endoscopy procedure, could have provided clues. In such patients, it is advisable to assure passage into the stomach before the capsule is struck in an extrinsic vascular stenosis in the oesophageal lumen.

E Redondo-Cerezo, A Pérez-Sola, C Gómez, G Pérez-Vigara, J I Pérez-García, J Morillas, J A González-Martin

Digestive Diseases Department, Gastrointestinal Endoscopy Unit, Hospital General Virgen de la Luz, Cuenca, Spain

Correspondence to: Dr E Redondo-Cerezo, Sección de Aparato Digestivo, Unidad de Endoscopias, Hospital General Virgen de la Luz, C/ Hernandad de Donantes de Sangre, 16002-Cuenca, Spain; eredondoc@yahoo.es
doi: 10.1136/gut.2004.051318

Conflict of interest: None declared.

References

Endogenous hepaticinoids in acute variceal bleeding

The risk of variceal bleeding in cirrhotics is associated with increasing liver dysfunction, larger varices, endoscopic red signs, and higher portal pressure. However, why bleeding occurs unpredictably and infrequently in individual patients is unknown. Bacterial infections occur in 35–66% of cirrhotics presenting with gastrointestinal bleeding. We proposed a possible pathophysiological basis linking infection and variceal bleeding via endotoxin induced endothelin release and subsequent portal pressure rise, combined with impaired platelet aggregation due to endotoxin induced nitric oxide and prostacyclin. Infected cirrhotics demonstrate a heparin effect using heparinase I modified thromboelastography (TEG) and have anti-Xa activity. Now we show similar findings in two cirrhotics during the course of acute variceal bleeding.

Patient 1 was male, 66 years old (Child-Pugh grade C), and patient 2 was female, 42 years old (Child-Pugh grade B), both with alcoholic cirrhosis. Both received endoscopic banding, intravenous terlipressin, and cefotaxime prophylactically as currently recommended. Baseline bacterial screens were negative with no subsequent infections. Blood samples after informed consent were taken at baseline (before any therapy) and subsequently over seven days. Heparinase I modified and standard TEG (Haemoscope Corp., Skokie, Illinois, USA) were performed simultaneously using only calcium activated citrated blood from the same sample 90 minutes after venepuncture: a heparin effect was defined as an improvement in r time, k time, and θ angle occurring together. Anti-Xa was assessed by chromogenic (Sigma Diagnostics, Poole, Dorset, UK) and clotting assays (Diagnostic Reagents, Thame, Oxford, UK).

A heparin effect was detected during one hour (patient 2) and six hours (patient 1) after the initial bleeding episode and persisted for 6–7 days, not fully corrected by fresh frozen plasma and/or red blood cells (fig 1) given during the first 24 hours. In patient 1, anti-Xa activity was positive during the same time span in which there was a heparin effect. Evaluated TEG parameters were ‘r time’ (time for the clot to start forming), ‘k time’ (time between the TEG trace reaching 2 mm and 20 mm), and ‘θ angle’ (the slope drawn

Figure 1 Comparison of standard and heparinase I modified thromboelastography with respect to r time in two patients with variceal bleeding.
from the \( \tau \) to the \( k \) value). These worsened over time: in patient 1, \( \tau \) time 11 minutes (four hours after the bleeding episode) to 18.8 minutes (six hours later); \( k \) time from 2.7 minutes to 7.3 minutes; and \( \alpha \) angle from 53.8° to 28.7°. In patient 2, \( \tau \) time increased from 11.2 minutes (one hour after the first haematemesis) to 33.8 minutes (two hours later); \( k \) time from 3.1 minutes to 10.7 minutes; and \( \alpha \) angle from 50.8° to 17.8°. These values slowly returned to baseline concomitantly with disappearance of the heparin effect after 6–7 days.

Routine coagulation parameters (prothrombin time, activated partial thromboplastin time) did not show any correlation with worsening TEG parameters or the heparin effect.

The presence of endogenous heparinoids in cirrhotic patients with acute variceal bleeding is clearly demonstrated. There was no evidence of infection but the antibiotic prophylaxis possibly prevented or treated infection. Neither patient experienced early rebleeding. The heparin effect was documented shortly after the beginning of the haemorrhage and disappeared over five days, over the same time course of antibiotic therapy. This was also seen by Montalto and colleagues.1 The absence of a demonstrable heparin effect at the beginning of bleeding and appearance thereafter could suggest that bleeding is a cause of its occurrence, and not the other way round. However, citrated blood may mask an initial less severe heparin effect and this needs to be evaluated compared with native blood. The heparin effect could influence continued variceal bleeding or early rebleeding. It is possible that the heparin effect might be more pronounced in the absence of antibiotics. This phenomenon deserves wider study, particularly as bacterial infection has been linked to failure to control variceal bleeding and early rebleeding, in a randomised study of prophylactic antibiotics.4

U Thalheimer, C Triantos, D Samonakis, D Patch, A K Burroughs
Liver Transplant and Hepatobiliary Medicine Unit, Royal Free Hospital, London, UK
A Riddell, D Perry
Haemophilia Unit, Royal Free Hospital, London, UK

Correspondence to: Professor A K Burroughs, Liver Transplant and Hepatobiliary Medicine Unit, Royal Free Hospital, Pond St, London NW3 2GG, UK; Andrew.Burroughs@royalfree.nhs.uk
doi: 10.1136/gut.2004.051474
Conflict of interest: None declared.

References

Changing epidemiology of IPSID in Southern Iran

Some 40 years ago physicians in the Middle East noted a high incidence and prevalence of upper small intestinal lymphoma.1 Later this condition was found to be associated with malabsorption as well as the presence of alpha heavy chain proteins.2 The disease was named by the WHO as “immunoproliferative small intestinal disease” (IPSID). One of the earliest reports of IPSID was from our centre.3 This study was designed to confirm the trend in the epidemiology of IPSID over the past 25 years in our medical centre. In a retrospective study (March 1974 to March 1999), we reviewed pathology reports from all surgical pathology laboratories in the province of Fars located in Southern Iran.

All reports, which were labelled as IPSID, were reviewed by one of the authors. Cases were grouped into five year intervals according to the date of the initial diagnosis and five year age groups. Age specific frequencies were calculated using midperiod population denominators for each age group, and summed. Age adjusted incidence rates were calculated by direct standardisation using the world standard population.6

During this 25 year period, more than 500 000 surgical pathology reports were recorded. There were 5421 gastrointestinal tract cancers of which 2326 (43%) were oesophageal cancers, and 536 (10%) small bowel cancers. Of the small bowel cancers, 161 (30%) cases were IPSID. This comprised 3% of all gastrointestinal cancers in this period.

Among the 161 IPSID cases, 98 (61%) were males with a mean age of 31.74 (SD 11.94) years and 63 (39%) were females (mean age 36.85 (8.88)). The standardised rate ratio (95% confidence interval) of males to females in the study was 1.39 (1.26, 1.69), which represents a higher incidence of IPSID in males. Almost all cases were village dwellers or those who had recently immigrated to large cities from their villages. Age specific rates and absolute frequency of IPSID in males and females are shown in table 1. The disease had its highest incidence in the third decade of life in both sexes. There has been a persistent decrease in the incidence of IPSID since 1986, as shown in fig 1.

The sharp decrease in the incidence of IPSID in the period 1978–1983 coincided with the time of revolution and the Iraq-Iran war, which caused instability in all organisations. The incidence of IPSID has decreased over the past 15 years (\( r^2 = 0.26, t (14) = -2.23, p = 0.04 \)). IPSID was once the most common small intestinal malignancy in the Middle East.5 Early infectious stress in infancy and chronic antigenic stimulation in the earlier part of life along with genetic factors are probably important in the pathogenesis of IPSID.7 In our series of 161 patients with IPSID, we observed a dramatic decrease in the incidence of the disease over the past decade.

After the Islamic revolution in Iran, improving sanitation in villages was one of the priorities of the many health strategies in Iran. Access to sanitary drinking water in rural areas increased from 35% before 1988 to 80% a decade later.5 Vaccination programmes increased dramatically after the Islamic revolution, reaching more than 90% of children.1 Local health facilities increased dramatically during the first two decades after the revolution.

Table 1 Age specific rates (ASR) and absolute frequency of immunoproliferative small intestinal disease in males and females in different age groups in the Fars province, Iran, from 1974 to 1999

<table>
<thead>
<tr>
<th>Age group (y)</th>
<th>Total</th>
<th>ASR Males</th>
<th>ASR Females</th>
<th>ASR</th>
<th>Total ASR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–4</td>
<td>2</td>
<td>0.02</td>
<td>0.02</td>
<td>0.02</td>
<td>0.02 (0.00–0.03)</td>
</tr>
<tr>
<td>5–9</td>
<td>6</td>
<td>0.05</td>
<td>0.10</td>
<td>0.06</td>
<td>0.06 (0.03–0.09)</td>
</tr>
<tr>
<td>10–14</td>
<td>3</td>
<td>0.05</td>
<td>0.08</td>
<td>0.05</td>
<td>0.05 (0.02–0.08)</td>
</tr>
<tr>
<td>15–19</td>
<td>1</td>
<td>0.17</td>
<td>0.03</td>
<td>0.05</td>
<td>0.06 (0.02–0.11)</td>
</tr>
<tr>
<td>20–24</td>
<td>35</td>
<td>0.54</td>
<td>0.49</td>
<td>0.48</td>
<td>0.48 (0.46–0.50)</td>
</tr>
<tr>
<td>25–29</td>
<td>35</td>
<td>0.59</td>
<td>0.62</td>
<td>0.60</td>
<td>0.60 (0.58–0.62)</td>
</tr>
<tr>
<td>30–34</td>
<td>37</td>
<td>0.25</td>
<td>0.31</td>
<td>0.28</td>
<td>0.28 (0.26–0.30)</td>
</tr>
<tr>
<td>35–39</td>
<td>6</td>
<td>0.43</td>
<td>0.38</td>
<td>0.41</td>
<td>0.41 (0.39–0.44)</td>
</tr>
<tr>
<td>40–44</td>
<td>1</td>
<td>0.38</td>
<td>0.33</td>
<td>0.36</td>
<td>0.36 (0.34–0.38)</td>
</tr>
<tr>
<td>45–49</td>
<td>10</td>
<td>0.42</td>
<td>0.37</td>
<td>0.44</td>
<td>0.44 (0.41–0.47)</td>
</tr>
<tr>
<td>50–54</td>
<td>7</td>
<td>0.32</td>
<td>0.36</td>
<td>0.34</td>
<td>0.34 (0.32–0.36)</td>
</tr>
<tr>
<td>55–59</td>
<td>5</td>
<td>0.28</td>
<td>0.31</td>
<td>0.30</td>
<td>0.30 (0.28–0.32)</td>
</tr>
<tr>
<td>60–64</td>
<td>2</td>
<td>0.12</td>
<td>0.22</td>
<td>0.13</td>
<td>0.13 (0.10–0.15)</td>
</tr>
<tr>
<td>&gt;65</td>
<td>2</td>
<td>0.13</td>
<td>0.25</td>
<td>0.16</td>
<td>0.16 (0.13–0.19)</td>
</tr>
<tr>
<td>Total</td>
<td>161</td>
<td>0.21</td>
<td>0.25</td>
<td>0.23</td>
<td>0.23 (0.21–0.25)</td>
</tr>
</tbody>
</table>

Age specific rate per 100 000 population in each age group.
We postulate that improvement in health in general and decreasing childhood gastroenteritides in particular has resulted in a decrease in the incidence of IPSID. This report highlights the almost complete disappearance of a malignant disease from a region where it was once very common. This is probably related to changes in environmental factors, decreasing exposure to infectious agents.

K B Lankarani, S M Masoompour, M B Masoompour, R Malekzadeh, S Z Tabei, M Haghshenas
Gastroenterology and Hepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Islamic Republic of Iran

Correspondence to: Dr K B Lankarani, Gastroenterology and Hepatology Research Center, Shiraz University of Medical Sciences, PO Box 71345-1414, Shiraz, Islamic Republic of Iran; Lankarani@sums.ac.ir
doi: 10.1136/gut.2004.0050526
Conflict of interest: None declared.

References

Microscopic (collagenous and lymphocytic) colitis triggered by food allergy

Collagenous and lymphocytic colitis are rare diseases of unknown aetiology but several issues, in particular the good response to budesonide, are suggestive of immunopathology. Patients have watery diarrhea without abnormal findings on colonoscopy but with increased numbers of intraepithelial lymphocytes, mast cells, and eosinophils on histological examination.

We report six patients seen between 1993 and 1999 who were first diagnosed as having collagenous/lymphocytic colitis. Signs of allergy entailed a work up for food allergy. (table 1).

All patients were investigated with skin prick testing, total and allergen specific IgE with food, and environmental allergens. Excretion of urine methylhistamine (UMH) was measured on a normal and hypoallergenic potato-rice diet. Colonoscopy with endoscopically guided segmental lavage for intestinal IgE was carried out and biopsies were investigated by routine pathology (haematoxylin-rosin), immunohistochemistry for eosinophil peroxidase, and amount of eosinophil cationic protein and tryptase in the whole biopsy. Clinical activity was mainly assessed by number of stools/day and the Karnofsky index for general performance.

After allergen identification, all patients were counselled on elimination of the allergen, except for one case where no allergen was identified. In this case, in a second patient with multiple sensitisations, and in a third with allergy to basal foods, additional cromolyn therapy was initiated. A trial of hypoallergenic diet and subsequent controlled addition of food with low allergenicity was performed. Additional antihistaminergic therapy (fexofenadine) was recommended as supplementary therapy for periods of exacerbation.

All patients were followed prospectively every 12 months after diagnosis (outpatient clinic and structured telephone interview) and all had symptom reduction in terms of stool frequency and consistency (table 2). General performance was completely restored in four patients and improved in one. The remaining patient is still very restricted in his activities due to incapacitating coronary artery disease but his gastrointestinal symptoms are tolerable.

Another patient was not willing to undergo colonoscopy for lavage and allergen identification, nor willing to quit smoking. His stools normalised after a six month course of cromolyn but he still suffers from bouts of diarrhoea during stress. He considers his general performance as good.

Histology was available for one patient before and after therapy. After dietary elimination, eosinophil infiltrate was markedly less dense and degranulated.

The mechanisms of diarrhoea in collagenous colitis include a pronounced diffusion of sodium and chloride ions. The mechanisms of diarrhoea in collagenous colitis include a pronounced diffusion of sodium and chloride ions. Allergens could induce increased eosinophil infiltration and enhance transforming growth factor β with increased collagen deposition. Eosinophils are highly susceptible to steroids which may explain the good response of collagenous colitis to budesonide.

In summary, a subgroup of patients with microscopic colitis suffer from food allergy. Further work up for allergy is sensible in those patients with a history of atopic disease or blood/tissue eosinophilia. Allergen elimination can decrease or abolish the need for medication. Antiallergic therapy can be added to the therapeutic regimen.

Table 2 Number of stools per day (Baerts score) before and after therapy

<table>
<thead>
<tr>
<th>Sex</th>
<th>Age (y)</th>
<th>Follow up (y)</th>
<th>Atopy</th>
<th>Signs of allergy</th>
<th>Diagnostic markers suggestive of allergy</th>
<th>Identified allergen</th>
</tr>
</thead>
<tbody>
<tr>
<td>F</td>
<td>49</td>
<td>5</td>
<td>+</td>
<td>Improvement by hypoallergenic diet</td>
<td>Eos in bx</td>
<td>Egg, pollen, house dust mite</td>
</tr>
<tr>
<td>M</td>
<td>45</td>
<td>5</td>
<td>-</td>
<td>Urticaria, improvement by cromolyn</td>
<td>Eos in bx</td>
<td>Spices, moulds, flours, celery, nuts, milk, maize, rice, apple, celery, soy</td>
</tr>
<tr>
<td>M</td>
<td>46</td>
<td>5</td>
<td>-</td>
<td>Pansusinnatitis</td>
<td>UMH</td>
<td>Maize starch</td>
</tr>
<tr>
<td>M</td>
<td>52</td>
<td>3</td>
<td>-</td>
<td>IgG deficiency</td>
<td>Eos in bx</td>
<td>Milk, egg, soy</td>
</tr>
<tr>
<td>M</td>
<td>71</td>
<td>9</td>
<td>+</td>
<td>Prick</td>
<td>Prick, RAST</td>
<td>Ananas</td>
</tr>
<tr>
<td>F</td>
<td>59</td>
<td>4</td>
<td>+</td>
<td>Prick</td>
<td>UMH</td>
<td></td>
</tr>
</tbody>
</table>

Eos in bx, eosinophil in colon biopsy; UMH, urine methylhistamine.
response to this article by Hata et al. We read with interest the article by Rutter and emphasized that there are two types of dye spray: the contrast method in which dye is used solely to contrast the irregularity of the surface, and the staining method in which dyes such as crystal violet and methylene blue are used to stain the colonic mucosa. The latter technique provides more detailed structure of neoplastic as well as non-neoplastic colonic mucosa, which may contribute to more precise diagnosis of dysplasia and inflammatory change than with the contrast method.

Hata et al. discussed the characteristics and correct selection of dyes. In particular, Hata et al. emphasized that there are two types of dye spray: the contrast method in which dye is used solely to contrast the irregularity of the surface, and the staining method in which dyes such as crystal violet and methylene blue are used to stain the colonic mucosa. The latter technique provides more detailed structure of neoplastic as well as non-neoplastic colonic mucosa, which may contribute to more precise diagnosis of dysplasia and inflammatory change than the contrast method.

However, as Hata et al. pointed out, a disadvantage of the staining method is that it is time consuming. Usually, this takes two or three minutes to stain one region. Therefore, it would be beneficial if there were an agent that demonstrated the fine structure of the colonic mucosa without a delay. Recently, we have introduced acetic acid spray in screening colonoscopy to visualize the fine structure of colonic neoplasia, in which approximately 5 ml of 2% acetic acid solution is sprayed toward the targeted lesion in the same manner as for indigo carmine. The advantages of using acetic acid spray as a staining method are as follows.

Firstly, the fine structure of the mucosa can be demonstrated immediately (fig 1A, B). Therefore, it reduces the time for examination, especially in patients with multiple lesions. Secondly, acetic acid effectively removes surface mucous material that interferes with magnifying observations (fig 1C, D). Lastly, acetic acid is less expensive.

We agree with Hata et al. that it is essential to understand the various methods of dye spray and to apply them appropriately, according to the situation. Here, we advocate acetic acid spray as an alternative to dye spray for enhancing the fine structure of the mucosa. Hata et al. tilted their letter “To dye or not to dye. That is beyond question!” We would like to add “To spray dye or to spray acetic acid. That is our question!”

**Infliximab failure in cap polyposis**

Cap polyposis is a rare condition that predominantly affects the rectosigmoid with distinctive clinicopathological features. The common symptoms are mucoid and bloody diarrhoea with abdominal pain and tenesmus. At endoscopy, polyps are red, sessile, and located at the apices of enlarged transverse mucosal folds with a normal intervening mucosa. Microscopic features include elongated hyperplastic looking glands with a mixed inflammatory infiltrate in the lamina propria. A cap of fibrinopurulent exudate covers the polyps. Treatment of this condition remains empiric. Metronidazole and steroids have been effective in some cases. Symptoms are often relieved by polypectomy but rectosigmoid resection may be required to control diarrhoea.

Some years ago, we reported in Gut on a 52 year old woman who needed sigmoid resection for cap polyposis.1 Following surgery, she did well until 1998 when she again complained of abundant mucoid diarrhoea with severe postprandial abdominal pain requiring daily antispasmodic therapy. A cap of fibrinopurulent exudate covers the polyps. Treatment of this condition remains empiric. Metronidazole and steroids have been effective in some cases. Symptoms are often relieved by polypectomy but rectosigmoid resection may be required to control diarrhoea.

Some years ago, we reported in Gut on a 52 year old woman who needed sigmoid resection for cap polyposis. Following surgery, she did well until 1998 when she again complained of abundant mucoid diarrhoea with severe postprandial abdominal pain requiring daily antispasmodic therapy. A cap of fibrinopurulent exudate covers the polyps. Treatment of this condition remains empiric. Metronidazole and steroids have been effective in some cases. Symptoms are often relieved by polypectomy but rectosigmoid resection may be required to control diarrhoea.

Some years ago, we reported in Gut on a 52 year old woman who needed sigmoid resection for cap polyposis. Following surgery, she did well until 1998 when she again complained of abundant mucoid diarrhoea with severe postprandial abdominal pain requiring daily antispasmodic therapy. A cap of fibrinopurulent exudate covers the polyps. Treatment of this condition remains empiric. Metronidazole and steroids have been effective in some cases. Symptoms are often relieved by polypectomy but rectosigmoid resection may be required to control diarrhoea.

We agree with Hata et al. that it is essential to understand the various methods of dye spray and to apply them appropriately, according to the situation. Here, we advocate acetic acid spray as an alternative to dye spray for enhancing the fine structure of the mucosa. Hata et al. tilted their letter “To dye or not to dye. That is beyond question!” We would like to add “To spray dye or to spray acetic acid. That is our question!”

**References**


Figure 1 (A) Magnifying chromoendoscopy using the contrast method. Indigo carmine spray reveals a neoplastic pattern. However, the pit pattern cannot be observed in some parts of the tumour. (B) After acetic acid spray, the detailed structure of the entire surface is immediately demonstrated more meticulously than with the contrast method. (C) Polyp covered with mucus. Dye spray using indigo carmine fails to reveal the surface structure because of the mucus. (D) After acetic acid spray, the mucous has been clearly removed and the surface of the polyp can be evaluated.

Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn’s disease

There is growing evidence that the efficacy of anti-tumour necrosis factor α (TNF-α) therapies in Crohn’s disease (CD) may critically depend on the binding of the transmembrane precursor of TNF-α (mTNF-α), thus eliciting complex intracellular signalling events, a process described as “reverse signalling”. In their recent paper (Gut 2004;53:70–7), Di Sabatino et al showed that infliximab reverted defective peripheral and lamina propria lymphocyte apoptosis in CD patients via a caspase dependent mechanism, further corroborating the findings of previous studies. It has also been suggested that failure of another TNF binding agent, etanercept (Enbrel; a recombinant TNFR2:Fc fusion protein), to induce peripheral and lamina propria lymphocyte apoptosis, provides a possible molecular explanation for the lack of efficacy of etanercept in a randomised placebo controlled trial in active CD.

References
4 Sadamoto Y, Jini S, Harada N, et al. Asymptomatic cap-polyposis from the sigmoid rectal mucosa using real time polymerase chain reaction before and after treatment, and compared with control values. Unfortunately, no clinical or endoscopic improvement occurred following infliximab infusions. TNF-α levels in the mucosa were not different compared with controls before and after treatment.

The reason for the discrepancy between this failure and the spectacular improvement observed by Bookman and colleagues is unclear. Our patient suffered from this condition for more than 10 years and may have had a more refractory form of the disease. One should also remember that in the case described by Bookman and colleagues, no control was available and spontaneous regression of cap polyposis has already been observed. The pathogenesis of cap polyposis remains unclear. Our data do not support the hypothesis that TNF-α plays a role in the pathogenesis of cap polyposis. An infectious or ischaemic aetiology has been suspected. Histological features similar to cap polyposis have been described in other disorders where mucosal prolapse is the underlying mechanism such as solitary rectal ulcer syndrome or prolapsed colostomies. It has therefore been suggested that abnormal colonic motility may be an important aetiological factor.

V Maunoury, M Breisse, P Desreumaux, L Gambiez, J-F Colombel Clinique des Maladies de l’Appareil Digestif et al de la Nutrition, Centre Hospitalier Universitaire Lille, Lille, France

Correspondence to: Professor J-F Colombel, Clinique des Maladies de l’Appareil Digestif et al de la Nutrition, Centre Hospitalier Universitaire Lille, CH et al U Lille, 59037, Lille, France; jfcolombel@chru-lille.fr

doi: 10.1136/gut.2004.053686

Conflict of interest: None declared.

www.gutjnl.com
However, the authors do not discuss other signalling pathways that are activated via ligation of transmembrane TNF-α by infliximab (for example, they have shown that infliximab also transiently activates p38 mitogen activated protein kinase (MAPK) in monocytes in vitro and in the lamina propria of CD patients in vivo1). Responders and non-responders to infliximab differ in the pattern of mucosal p38MAPK target phosphorylation, but not caspase-3 activation, further emphasizing the complex modulation of intracellular signalling pathways beyond mere neutralisation of TNF-α. To show if these signalling pathways are also activated in primary T cells, we analysed the influence of infliximab and etanercept on p38MAPK activation and apoptosis in an established model of non-transformed in situ activated T lymphocytes.  

According to the findings of van den Brande et al., we observed PARP cleavage as a molecular hallmark of apoptosis in cultures grown with infliximab (fig 1A) but not in the presence of etanercept. Whereas no increase in phosphorylated p38MAPK could be detected after etanercept stimulation, significant activation (that is, dual phosphorylation of p38) in 24 hours after infliximab treatment was observed in 4/5 of the cell lines derived from CD patients (fig 1A).  

We have demonstrated previously that constitutive tyrosine phosphorylation of the transcription factor signal transducer and activator of transcription 3 (STAT3) may represent a specific feature of intestinal T cells from Crohn’s disease. Tyrosine phosphorylated STAT3 can be found in CD4 modulatory role in chronic intestinal inflammation and non-apoptotic signalling may have important implications for the design of future therapeutic strategies in inflammatory bowel disease.

P Rosentiel  
Institute of Clinical Molecular Biology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

J Agnolt, J Kelsen  
Department of Medicine V, Aarhus University Hospital, Aarhus, Denmark

V Medici  
Institute of Clinical Molecular Biology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

G H Waetzig, D Seegert  
Conaris Research Institute, Kiel, Germany

S Schreiber  
Institute of Clinical Molecular Biology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

Correspondence to: Professor S Schreiber, Institute of Clinical Molecular Biology, University Hospital Schleswig-Holstein, Campus Kiel, 24305 Kiel, Germany; s.schreiber@muco.de

Conflict of interest: None declared.

References


Author’s reply

We thank Rosentiel et al for their interest in our paper regarding the role of the chimeric anti-tumour necrosis factor (TNF-α) antibody, infliximab, in reverting defective lamina propria T cell apoptosis in Crohn’s disease via a caspase dependent pathway (Gut 2004;53:70–7).

In their interesting letter, Rosentiel et al investigate the complex TNF-α blocker molecule in Crohn’s disease by analysing the influence of infliximab and recombiant TNF receptor/immunoglobulin G fusion protein, etanercept, on p38 mitogen activated protein kinase (MAPK) activation, apoptosis, and signal transducer and activator of transcription 3 (STAT3) tyrosine phosphorylation in lamina propria T cells from active Crohn’s disease patients. Infliximab, but not etanercept, has been shown to result in p38MAPK activation and apoptosis, while both of these agents were able to reduce STAT3 phosphorylation in Crohn’s disease lamina propria T cells.

If data on the differences in mucosal T cell apoptosis inducing capacity of infliximab and etanercept are in keeping with the results obtained by van den Brande and colleagues, the observation that infliximab induces activation of a proinflammatory MAPK does not tally with the evidence that the guanylylhydrazone c-Jun N terminal kinase/p38 inhibitor CN1-1493 induces clinical improvement in steroid resistant Crohn’s disease patients. The reason for this discrepancy probably lies in the complex and dichotomous role of p38MAPK in inflammatory signal transduction. p38MAPK inhibition is efficacious in chronic inflammatory disease but not in acute experimental colitis, where it causes adverse effects, and it shares differential actions in different T cell subpopulations. In naïve T cells, in fact, the protein kinase SB203580 inhibits proinflammatory cytokine production whereas in TH type 1 cells it does not affect TNF-α release but strongly impairs anti-inflammatory interleukin 10 production; this supports the diversity between Th1 and Th2 cytokines to the former.

Since several lines of evidence have also suggested the proapoptotic role of the p38 pathway, Warzig and colleagues hypothesised that the increased phosphorylation of the p38MAPK downstream effector ATF-2, found after infliximab treatment only in responder Crohn’s disease patients, could enhance infliximab induced apoptosis of immune cells in this subgroup of patients. However, the similar proportion of lamina propria immune cell apoptosis after infliximab treatment in both responders and non-responders suggests that the downstream MAPK pathway is not related to infliximab induced immune cell apoptosis.

Disturbances in STAT signalling pathways, which transduce the numerous immunomodulatory messages of most of cytokines/cytokine receptors, have been shown to be involved in the pathogenesis of Crohn’s disease. In particular, STAT1 and STAT3 proteins are constitutively activated in lamina propria CD4+ T cells from active Crohn’s disease patients. The finding of Rosentiel et al that both infliximab and etanercept are able to reduce in vitro STAT3 tyrosine phosphorylation in Crohn’s disease lamina propria T cells is probably related to the capacity of both of these agents to neutralise soluble TNF-α. Interestingly, the absence of quantitative differences in the phosphorylation of STAT1 in the blocker and etanercept in downregulating STAT3 signalling is consistent with the data of van den Brande and colleagues who have shown that both drugs can neutralise soluble TNF-α to a similar extent. Taken together, these findings suggest that both the apoptotic and non-apoptotic intracellular signalling pathways underlying the therapeutic benefit of anti-TNF-α strategies in Crohn’s disease are multifaceted and more complex than initially thought. Dissecting the MAPK signalling cascades that are selectively activated in the abnormal immune response
of inflammatory bowel disease is critical in the identification of selective targets and development of new and rational therapies for the treatment of Crohn's disease.

A Di Sabatino, R Ciccocioppo, R Morera, G R Corazza
Gastroenterology Unit, IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy

Correspondence to: Dr A Di Sabatino, Gastroenterology Unit, IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy; a.disabatino@smatteo.pv.it

Conflict of interest: None declared.

References

BOOK REVIEW

Small and Large Intestine

The Small and Large Intestine, one of four volumes in this series named the Requisites in Gastroenterology edited by Anil Rustgi of the University of Pennsylvania, provides a refreshing readable overview. While successfully avoiding entrenchment in detailed consideration of the scientific literature, it provides a mainstream viewpoint of the major issues. It is presented in a logical and clear manner aimed at achieving an understanding at a basic level which will provide the reader with a good platform to focus on specific areas with more in depth study. In this series, Rustgi moves away from an account of the substantial gastroenterological literature which often includes clinical trials with apparently contradictory conclusions that may lead to controversies unwarranted by the novice. Rather than being expected to weigh up the evidence, the student is more usually interested in the general viewpoint of the main body of experts. This series avoids the comprehensive consideration of the literature often found in the larger reference texts and concentrates on the delivery of practical guidance and the acquisition of a general grasp of the subject, particularly for physicians in training and medical students.

Each of the 13 chapters have well defined formats, orientating the reader with a brief initial chapter outline and general introduction to the subject. The majority then discuss the epidemiology and pathophysiology before providing a more detailed account of clinical evaluation and treatment. Considerable attention is given to pragmatic clinical management issues cutting through much of the academic detail to provide practical information, useful to those considering the day to day issues of gastroenterology. For example, in the Crohn’s disease chapter, there are two pages dedicated to phenogenesis, five to clinical assessment and diagnosis, followed by 16 pages on therapy of which only one relates to surgery, and that includes a table (clearly we are heading in the right direction with therapy!). However, nutritional therapy is given very little mention, which may reveal subtle differences in the character of medical gastroenterology between the USA and Europe.

Most chapters stay well within general dogma, including the most important, latest, and robust advances in knowledge; a few have a particular emphasis. The ‘‘irritable bowel syndrome’’ chapter develops the psychosocial/psychiatric approach to patients to a degree that might reflect the chapter author’s own clinical experience as a professor of psychiatry and medicine. It nevertheless addresses the other pathogenic aspects of irritable bowel syndrome, although promotes rather strict Rome criteria to the diagnosis which perhaps does not describe the full range of irritable bowel syndrome patients seen in the average outpatient clinic and is of more value if a well defined group of patients is required, such as for conducting clinical trials. A positive diagnosis based on irritable bowel syndrome symptoms is also recommended. This should be tempered with caution as there are many pitfalls associated with this particular group of patients, particularly for those less experienced in this field of practice who are the target audience for this textbook. The chapters on ‘‘intestinal polyposis syndromes and hereditary colorectal neoplasia’’ and ‘‘colorectal cancer’’ perhaps by necessity, stray somewhat from the clinical emphasis to include a more detailed account of the pathogenesis and epidemiology. They cover the basic genetic aspects in rather more detail than is the trend in other chapters and offer more discussion of the evidence base rather than being confined to expert interpretation and opinion. This perhaps deflects from the needs of the intended target audience towards those more familiar with the subject. As with the other chapters, there is also a degree of overlap between these two chapters, which is particularly related to the clinical and genetic criteria for diagnosis of HNPC and the polyposis syndromes, and the criteria for genetic testing and screening. Both chapters are well written and interesting but it might have been more in keeping with the aims of the book to have combined them and kept to a more clinical direction with therapy!). However, nutrition therapy is given very little mention, which may reveal subtle differences in the character of medical gastroenterology between the USA and Europe.

There is a strong sense that this text has been prepared with certification and recertification of North American Physicians in mind but it is also well suited to medical students in the broader sense, perhaps revising for finals, MRCP candidates, and medical registrars in training. Although not referenced, each chapter offers a guide to further reading providing a useful introduction to the scientific literature. In this volume, editors Lichtenstein and Wu achieve the aims of the series, as indicated by Anil Rustgi, the editor in chief in his foreword, to provide a user friendly text, imparted with expert knowledge and insights, that together constitute an overview and refresher course aimed at those training in the field of gastroenterology and those in other areas of medicine who want a succinct pragmatic overview.

S J Middleton

CORRECTION

doi: 10.1136/gut.2003.035113corr1

The spelling of one of the authors in the paper by Byrne et al (CD4+CD45RBhi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin, 2005;54:78–86), published in the January 2005 issue, was incorrect. R Manoukian should read R Manoukian.